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In an attempt to de®ne genomic copy number
changes associated with the development of basal
cell carcinoma, we investigated 15 sporadic tumors
by comparative genomic hybridization. With the
incorporation of tissue microdissection and degener-
ate oligonucleotide primed-polymerase chain reac-
tion we were able to isolate, and then universally
amplify, DNA from the tumor type. This combined
approach allows the investigation of chromosomal
imbalances within a histologically distinct region of
tissue. Using comparative genomic hybridization we
have observed novel and recurrent chromosomal
gains at 6p (47%), 6q (20%), 9p (20%), 7 (13%), and
X (13%). In addition comparative genomic hybridi-
zation revealed regional loss on 9q in 33% of tested
tumors encompassing 9q22.3 to which the putative
tumor suppressor gene, Patched, has been mapped.
The deletion of Patched has been indicated in the
development of hereditary and sporadic basal cell
carcinomas. The identi®cation of these recurrent
genetic aberrations suggests that basal cell carcino-
mas may not be as genetically stable as previously
thought. Further investigation of these regions may
lead to the identi®cation of other genes responsible
for basal cell carcinoma formation. Key words: basal
cell carcinoma/comparative genomic hybridization/patched/
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B
asal cell carcinoma (BCC) accounts for more than 75%
of nonmelanoma skin cancers diagnosed, making it the
most prevalent malignancy throughout Caucasian
populations in Australia and the United States
(Miller, 1991; Miller and Weinstock, 1994). BCC are
considered malignant due to their ability to locally in®ltrate
surrounding tissue; however, they rarely metastasize. If neglected,
they may in®ltrate deeply, destroying local tissue; this is of
particular importance when situated near the eye, nose, or ear.
Nodular BCC are the most predominant (45%±60%) subtype of
BCC and are found almost exclusively in sun-exposed regions of
the body, with super®cial BCC being the second most prevalent
(15%±30%) type (Preston and Stern, 1992).
The analysis of BCC progression has been mainly concerned
with a rare genetic disorder known as nevoid basal cell carcinoma
syndrome (NBCCS). Also known as Gorlin's syndrome, this
disease shows a propensity for multiple BCC development.
Genetically NBCCS has been associated with a regional deletion
at 9q22.3. Physical mapping of this locus led to the identi®cation of
the putative tumor suppressor gene Patched (PTCH) (Hahn et al,
1996; Johnson et al, 1996). In addition, loss or mutation of PTCH
has been implicated in a third of sporadic BCC development
(Gailani et al, 1996). Studies have shown that the deregulation of
the hedgehog pathway is altered in a proportion of sporadic BCC
(Aszterbaum et al, 1999); however, it is likely that other uniden-
ti®ed genetic events may also be involved.
Loss of heterozygosity (LOH) studies by Quinn et al (1994) have
also indicated a high frequency of loss on 9q (59%), in sporadic
BCC. Allelic loss on other chromosome arms were uncommon,
however. The study relied upon the allelic loss of one locus per
chromosome arm, thus leaving the majority of the genome
unexamined. Copy number increases were also not investigated.
Cytogenetic analysis has proven dif®cult due to associated problems
with culturing BCC cells without ®broblast selection bias. Cultures
having an epithelial growth pattern have shown recurrent numer-
ical abnormalities of +18, +9, +20, +7, and +5, in addition to
structural rearrangements of the 9q arm (Jin et al, 1998). A more
recent study identi®ed nonrandom numerical changes involving +6
by cytogenetics and interphase FISH analysis in 38% of direct
cultures analyzed (Casalone et al, 2000).
Since its development, comparative genomic hybridization
(CGH) has provided additional insights into genetic changes
involved in the formation of numerous solid tumor types (for
reviews see Forozan et al, 1997; Zitzelsberger et al, 1997; Knuutila
et al, 1998). Brie¯y the technique enables anonymous DNA copy
number aberrations within the entire tumor genome to be mapped
to normal chromosomes for subsequent identi®cation without the
dif®culties associated with complex tumor karyotypes (Kallioniemi
et al, 1992; 1994). Regions of aberration identi®ed initially from
CGH data have led to the discovery of previously unknown
putative cancer genes including NABC1 and ZNF217 in breast
cancer development (Collins et al, 1998), the androgen receptor in
prostate cancer, and PIK3CA in ovarian carcinoma (Visakorpi et al,
1995; Shayesteh et al, 1999).
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Because the amount of pure tumor DNA is limited in archival
material, we incorporated the use of tissue microdissection to purify
the tumor cell population and degenerate oligonucleotide primed-
polymerase chain reaction (DOP-PCR). This ampli®cation tech-
nique is universal and linear providing adequate quantities of DNA
for subsequent CGH analysis (Telenius et al, 1992). The combin-
ation of tissue microdissection and DOP-PCR to prepare suitable
DNA for CGH analysis has been implemented with great success in
many previous studies (Speicher et al, 1995; Wiltshire et al, 1995;
KuukasjaÈrvi et al, 1997a, b).
We report here the analysis of 15 BCC using CGH; such analysis
identi®ed recurrent chromosomal gains of 6p, 6q, 7, 9p, and X. In
addition, genetic loss at 9q encompassing the PTCH locus was
observed, and further investigated by LOH.
MATERIALS AND METHODS
Tumor samples Formalin-®xed, paraf®n-embedded tissue sections
from 15 BCC (12 nodular and three super®cial) were obtained from the
Department of Pathology, Gold Coast Hospital. These tumors were
histopathologically examined and classi®ed as characteristic sun-induced
BCC.
Tissue microdissection Three consecutive 5 mm sections were cut
from each paraf®n-embedded tissue block. The middle section was
stained with hematoxylin and eosin and used to identify histologic
representative regions of the tumor. An adjacent section was stained with
methyl green using standard techniques to be used in manual
microdissection. Tumor tissue was removed and incubated in 30 ml of
digestion buffer [10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM
MgCl2, 0.4 mg per ml proteinase-K, 0.5% Tween 20] at 55°C for 3 d.
Fresh proteinase-K (0.6 ml of 20 mg per ml stock) was added to the
digestion each day. On the third day digestion was inhibited by a 10 min
95°C incubation.
DOP-PCR ampli®cation and DNA labeling The universal
ampli®cation by DOP-PCR of extracted tumor DNA was performed
essentially as described by KuukasjaÈrvi et al (1997a). Normal reference
DNA was extracted from the blood lymphocytes of karyotypically
normal male or female volunteers using standard techniques. DOP-PCR
products from normal and tumor DNA were labeled via nick translation
according to Kallioniemi et al (1994) with Texas Red-5-dUTP and
¯uorescein-12-dUTP (FITC) (DuPont, Boston, MA), respectively.
Products of the size 150±2000 bp for normal and some DNA greater
than 300 bp for tumor were deemed suitable for CGH.
CGH and digital image analysis CGH was performed essentially as
described by Kallioniemi et al (1992, 1994) on normal male lymphocyte
metaphase spreads from Vysis (Downers Grove, IL). After a 3 d
hybridization at 37°C slides were washed and counterstained with DAPI
according to Pinkel et al (1988). Metaphases were examined under an
Olympus BX-60 microscope (Tokyo, Japan) equipped with appropriate
epi¯uorescent ®lters and a CCD camera interfaced to a PowerMacintosh.
Three images of each metaphase were captured using single band
excitation DAPI, FITC, and Texas Red ®lters, and a cube-mounted
quadruple band pass dichroic and emission ®lter (Chroma Technology,
Brattleboro, VT). Image acquisition, pro®le generation, and analysis were
performed using the MacProbe v.4.1 PowerGene CGH module
(Perceptive Scienti®c International, Chester, U.K.). After karyotyping
the green-to-red ratio pro®les were calculated down the axis of each
chromosome. Data from six or more homologous chromosomes were
used to generate a mean pro®le 6 1 standard deviation (SD) per
hybridization. Threshold values of 1.2 and 0.8 (based on measurements
from a series of ®ve sex-mismatched controls) were set to identify the
presence of gains and losses, respectively. Regions whose mean ratio was
Figure 1. Summary of genetic imbalances detected by CGH in 15 BCCs. Losses are indicated by lines to the left of each chromosome, whereas
lines to the right represent gains. The entire Y chromosome was excluded from analysis.
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less than 0.8 were classi®ed as a loss and greater than 1.2 a DNA gain.
The average pro®les for all the tumors investigated were combined to
identify recurrent copy number changes.
Controls A negative control (no template DNA) was included in each
DOP-PCR, with all products discarded if any ampli®cation was
observed in this control. In addition, a positive CGH control slide using
MPE600 or MCF-7 breast cancer DNA was included in each
hybridization batch to validate that conditions were adequate for
detecting all known aberrations. Finally, inverse CGH (i.e., FITC-
labeled normal reference and Texas Red-labeled tumor DNA) was also
performed particularly when problematic regions prone to labeling and/
or hybridization artefacts were shown to undergo gain or loss
(Kallioniemi et al, 1994; Larramendy et al, 1998). Copy number changes
were scored only if present in both standard and inverse CGH. Finally
DNA from normal skin punches were examined by CGH and showed
no deviations from normal ratio pro®les, con®rming that no
methodologic artefacts were produced.
LOH Four polymorphic microsatellite markers located between 9q21
and 9qter (D9S53, D9S15, D9S287, and D9S303) were used to assess
allele loss in paired tumor and normal DNAs, essentially as described by
Shen et al (1999). Primer sequences were extracted from the Genome
Database via the Internet (http://www.gdb.org). The forward primer in
each pair was ¯uorescently 5¢-end labeled to enable accurate
quantitation. The PCR products were processed on an ABI 310 Genetic
Analyzer (Applied Biosystems, Foster City, CA) with subsequent analysis
using Genescan software for size, peak height, and peak area. The
method described by Cawkwell et al (1993) was used to detect LOH,
determining the allelic imbalance of a tumor (T1:T2) to the imbalance in
normal DNA (N1:N2) using the expression T1:T2/N1:N2 or 1/
(T1:T2/N1:N2) if the allele ratio was above 1.0. Allele ratio values less
than or equal to 0.6 were scored as LOH.
RESULTS
CGH analysis To evaluate the presence of DNA sequence copy
number changes in BCC we performed CGH on 15 separate cases.
Evidence of chromosomal imbalances were identi®ed in 80% (12 of
15) of tumors analyzed. Of these tumors the common number of
aberrations was 1.9 6 1.5 SD. A summary of all copy number
changes detected by CGH are shown in Fig 1 and together with
clinical and histologic data for each tumor are listed in Table I.
Regions of chromosomal gain and loss DNA sequence copy
number increases were identi®ed in nine out of 15 cases (60%).
Recurrent changes were observed at 6pter-p21 (47%), 6q (20%), 9p
(20%), 7 (13%), and X (13%). Regional gain of 9p was always
associated with 6p over-representation. Other less frequent gains at
20 and 18q were also observed. Genetic loss detected by CGH was
con®ned exclusively to chromosome 9. Five of 15 cases studied
(33%) showed a deletion at this locus. The common and recurrent
loss of 9q22 is believed to be a distinct event in BCC development
and has been associated with the inactivation of the PTCH tumor
suppressor gene.
LOH Con®rmation of 9q loss was performed via LOH analysis
using four microsatellite markers mapping to this region; Fig 2
summarizes these results. LOH was identi®ed in 19 out of 42 (45%)
informative loci. A general overview of LOH identi®ed eight out
of 15 cases (53%) with one or more loci displaying allelic loss, at or
near the PTCH locus. All regional losses of 9q identi®ed by CGH
were con®rmed by LOH analysis.
DISCUSSION
This study offers the ®rst insight into a genome-wide scan of shared
copy number changes in BCC as revealed by CGH. Such an
approach provides a comprehensive screening of the entire tumor
genome in a single hybridization. Although CGH does not de®ne
all structural rearrangements, it does detect common genetic copy
number abnormalities that are present in a large proportion of the
tumor population, hence those aberrations most likely to be clonal
in origin. In addition, the distinction between genetic gains and
losses and detailed information of chromosomal breakpoints
supports the use of CGH as a powerful and informative application.
Finally, the incorporation of tissue microdissection and DOP-PCR
enables the identi®cation of potentially important genetic changes,
which may be overshadowed when analyzing DNA from a large
cell population, particularly in polyclonal tumors.
Figure 2. Pattern of loss on chromosome 9q22 in BCC showing
LOH. The proportion of informative tumors showing LOH is given.
Solid box: loss of heterozygosity; open box: no loss of heterozygosity;
hatched box: noninformative.
Table I. Summary of selected clinical data, histologic diagnosis, and CGH results associated with each investigated BCC
Tumor no. Sex Age Tumor location Histologic diagnosis Regional gains Regional losses
1 F 67 Temple Nodular ± 9q21-q31
2 M 92 Ear Nodular 20 ±
3 M 69 Shoulder Nodular 6, 11, 18q21-qter ±
4 M 75 Forehead Nodular ± ±
5 M 61 Eyelid Nodular ± ±
6 M 80 Nostril Nodular 5q11-q14, 6, 7, 17, X ±
7 M 66 Ear Nodular 6pter-p21, 9pter-p13 ±
8 F 49 Ear Nodular 3q21-qter, 6pter-p21, 9pter-p21, 13q14-qter ±
9 M 67 Forehead Nodular 7, X 9q22-qter
10 F 42 Arm Super®cial 6pter-p22, 9p 9q22-qter
11 F 55 Shoulder Super®cial 6p, 14q21-qter ±
12 F 86 Ear Nodular ± 9
13 F 78 Cheek Nodular ± ±
14 F 70 Cheek Nodular 6 ±
15 F 87 Wrist Super®cial ± 9q22-qter
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In this study CGH analysis of BCC tumors identi®ed recurrent
chromosomal gains mapping to 6p (47%), 6q (20%), 9p (20%), 7
(13%), and X (13%). Other less frequent gains at 20 and 18q were
also observed. The occurrence of some of these abnormalities have
been previously described through cytogenetic analysis (Jin et al,
1998; Casalone et al, 2000). The CGH analysis provides additional
evidence that these are nonrandom changes and may be important
genetic events in BCC tumorigenesis. Of particular interest is the
over-representation of 6p (minimal overlap of 6pter-p21) in seven
of 15 (47%) tumors investigated. This novel change correlates well
with the ®ndings of Casalone et al (2000) who identi®ed recurrent
trisomy of chromosome 6 in direct preparations of BCC. Over-
representation of 6p has been previously identi®ed in bladder,
breast, ovarian, and nonsmall-cell lung carcinoma. Additionally
recurrent 6p gains have been observed in Merkel cell carcinoma,
cutaneous melanoma, and uveal melanoma (for review see Knuutila
et al, 1998). This suggests that 6p may be a common chromosomal
aberration in skin neoplasia. Of further interest is that all cases
identi®ed with an over-representation of 9p also showed a regional
gain of 6p. No correlation between this association and clinical or
histologic appearance was observed in these cases. The signi®cance
of this concurrent gain of 6p and 9p is currently unclear. In this
study it was observed in a limited number of samples and to our
knowledge has not been observed in other tumors examined by
CGH.
Loss at 9q22 was revealed in 33% of BCC studied using CGH
and 53% using LOH. These results are concordant with previous
data (Quinn et al, 1994; Shen et al, 1999). The frequency of loss
detected by LOH is generally higher than that reported by CGH
studies due to the ability of LOH to detect very small deletions and
differentiate between alleles over a diploid background (Tirkkonen
et al, 1998). The detected regional loss of 9q22 has been implicated
in hereditary and sporadic BCC due to the inactivation of the
PTCH tumor suppressor gene, a known regulator of the hedgehog
pathway (Gailani et al, 1996). Deletion involving chromosome 9
was the only genetic loss observed.
In this study a number of chromosomal gains were also detected.
These gains may indicate additional mechanisms in BCC
tumorigenesis aside from the mutation or loss of PTCH. Further
analysis into the intratumor heterogeneity and the activity and
mutational status of PTCH, however, needs to be addressed to
support this hypothesis. Interestingly, clonality studies involving
BCC have suggested that at least 60% of these tumors are
monoclonal (Walsh et al, 1998). In addition, mutational analysis of
PTCH has implicated the involvement of this locus in only a third
of sporadic BCC (Gailani et al, 1996), therefore suggesting
additional gene involvement.
In conclusion, we have demonstrated that BCC may be more
genetically unstable than previously thought. The identi®cation of
recurrent regions of imbalance, particularly 6pter-p21 and 9p,
warrants further analysis of these loci. Molecular characterization of
genes at these loci may help in understanding the underlying
molecular mechanisms of BCC pathogenesis and help delineate the
average progression pathway of BCC development.
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